Inhaled pre-prandial human insulin with the AERx[Rm] iDMS versus s.c. insulin aspart in type 2 diabetes: a 104 week, open-label, multicenter, randomised, trial followed by a 12 week re-randomised extension to investigate safety and efficacy.

Trial Profile

Inhaled pre-prandial human insulin with the AERx[Rm] iDMS versus s.c. insulin aspart in type 2 diabetes: a 104 week, open-label, multicenter, randomised, trial followed by a 12 week re-randomised extension to investigate safety and efficacy.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Insulin (Primary) ; Insulin aspart; Insulin detemir
  • Indications Type 2 diabetes mellitus
  • Focus Biomarker; Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Oct 2012 Planned number of patients changed from 546 to 710.
    • 24 Jun 2008 The expected completion date for this trial is now 1 May 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top